Plasma B-type natriuretic peptide in dialyzed patients: Marker of cardiovascular disease or link to plasma refilling?

Journal of Nephrology

Volumn 24, Issue 4, 2011, Pages 507-514

  de Mauri, Andreana ^a   Bellomo, Giorgio ^a   Navino, Carlo ^a   David, Paola ^a   Chiarinotti, Doriana ^a   Capurro, Federica ^a   Brustia, Maddalena ^a   de Maria, Mariangela ^a   Ruva, Carlo Edoardo ^a   Ciardi, Laura ^a   de Leo, Martino ^a  

^a MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

Author keywords

B type natriuretic peptide; Blood volume; Cardiovascular disease; Plasma refilling

Indexed keywords

ALDOSTERONE; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; RENIN; TROPONIN I;

AGED; ARTICLE; B TYPE NATRIURETIC PEPTIDE BLOOD LEVEL; BLOOD VOLUME REDUCTION RATE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DIABETES MELLITUS; EXTRACELLULAR SPACE; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIAFILTRATION; HEMODIALYSIS PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PLASMA RENIN ACTIVITY; PROTEIN BLOOD LEVEL; SURVIVAL RATE; ULTRAFILTRATION;

AGED; AGED, 80 AND OVER; ALDOSTERONE; BIOLOGICAL MARKERS; BLOOD VOLUME; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; EXTRACELLULAR FLUID; FEMALE; FLUID SHIFTS; HEMODIAFILTRATION; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; RENIN; TROPONIN I; WEIGHT LOSS;

EID: 79960325303     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/JN.2011.6240     Document Type: Article

References (31)

1. Woodard GE, Rosado JA. Recent advances in natriuretic peptide research. J Cell Mol Med. 2007;11:1263-1271.
2. Martinez-Rumayor A, Richards AM, Burnett JC, Januzzi JL. Biology of natriuretic peptides. Am J Cardiol. 2008;101:3-8.
3. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004;350:647-654.
4. Burke MA, Cotts WG. Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. Heart Fail Rev. 2007;12:23-36.
5. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50:2357-2368.
6. Suresh M, Farrington K. Natriuretic peptides and the dialysis patients. Semin Dial. 2005;18:409-419.
7. Clerico A, Caprioli R, Del Ry S, Giannessi D. Clinical relevance of cardiac natriuretic peptides measured by means of competitive and non-competitive immunoassay methods in patients with renal failure on chronic hemodialysis. J Endocrinol Invest. 2001;24:24-30.
8. Ishizaka Y, Yamamoto Y, Fukunaga T, et al. Plasma concentration of human Brain Natriuretic Peptide in patients on Hemodialysis. Am J Kidney Dis. 1994;24:461-472.
9. Nitta K, Kawashima A, Yumura W, et al. Plasma concentration of brain natriuretic peptide as an indicator of cardiac ventricular function in patients of hemodialysis. Am J Nephrol. 1998;18:411-415.
10. Racek J, Kràlovà H, Trefil L, et al. Brain natriuretic peptide and N-terminal ProBNP in chronic hemodialysis. Nephron Clin Pract. 2006;103:c162-c172.
11. Zucchelli P. Hemodialysis-induced symptomatic hypotension: a review of pathophysiological mechanism. Int J Artif Organs. 1987;10:139-144.
12. Lee SW, Song JH, Kim GA, Kim M. Plasma brain natriuretic peptide concentration of assessment of hydration status in hemodialysis patients. Am J Kidney Dis. 2003;41:1257-1266.
13. Daurgidas JT. Dialysis hypotension: a hemodynamic analysis. Kidney Int. 1991;39:233-246.
14. Santoro A, Mancini E, Basile C, et al. Blood volume controlled hemodialysis in hypotension-prone patients: a randomized multicenter controlled trial. Kidney Int. 2002;62:1034-1045.
15. Paolini F, Mancini E, Bosetto A, Santoro A. Hemoscan: a dialysis machine-integrated blood volume monitor. Int J Artif Organs. 1995;18:487-494.
16. Buckley MG, Sethi D, Markandu ND, et al. Plasma concentrations and comparisons of brain natriuretic peptide and atrial natriuretic peptide in normal subjects, cardiac transplant recipients and patients with dialysis-independent or dialysisdependent chronic renal failure. Clin Sci. 1992;83:437-444.
17. Zoccali C, Mallamaci F, Benedetto FA, et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol. 2001;12:1508-1515.
18. Matayoshi T, Kato T, Nakahama H, et al. Brain natriuretic peptide in hemodialysis patients: predictive values for hemodynamic change during hemodialysis and cardiac function. Am J Nephrol. 2008;28:122-127.
19. Osajima A, Okazaki M, Kato H, et al. Clinical significance of natriuretic peptides and cyclic GMP in hemodialysis patients with coronary artery disease. Am J Nephrol. 2001;21:112-119.
20. Fagugli RM, Palumbo B, Ricciardi D, et al. Association between brain natriuretic peptide and extracellular water in hemodialysis patients. Nephron Clin Pract. 2003;95:c60-c66.
21. Sheen V, Bhalla V, Tulua-Tata A, et al. The use of B-type natriuretic peptide to assess volume status in patients with endstage renal disease. Am Heart J 2007 Feb;153(2):244. e1-5.
22. Del Vecchio L, Procaccio M, Viganò S, Cusi D. Mechanisms of disease: the role of aldosterone in kidney damage and clinical benefits of its blockade. Nat Clin Pract Nephrol. 2007;3:42-49.
23. Sato A, Funder JW, Saruta T. Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis. Am J Hypertens. 1999;12(9 Pt 1):863-867.
24. Sasamura, et al. Response of plasma immunoreactive active renin, inactive renin, plasma renin activity and aldosterone to hemodialysis in patients with diabetic nephropathy. Clin Nephrol. 1990;33:288-292.
25. Basile C, Giordano R, Vernaglione L, et al. Efficacy and safety of hemodialysis treatment with the hemocontrol biofeedback system: a prospective medium-term study. Nephrol Dial Transplant. 2001;16:328-334.
26. Moon-Wang AY, Lai KN. Use of cardiac biomarkers in endstage renal disease. J Am Soc Nephrol. 2008;19:1643-1652.
27. Forrester DL, Britton J, Lewis SA, et al. Impact of adopting low sodium diet on biomarkers of inflammation and coagulation: a randomized controlled trial. J Nephrol. 2010;23:49-54.
28. Cerasola G, Nardi E, Palermo A, Mule G, Cottone S. epidemiology and pathophysiology of left ventricular abnormalities in chronic kidney disease: a review. J Nephrol 2010 May 2 (in press).
29. Sommerer C, Giannitsis E, Schwenger V, Zeier M. Cardiac biomarkers in hemodialysis patients: the prognostic values of amino-terminal-pro-B-type natriuretic peptide and cardiac troponin T. Nephron Clin Pract. 2007;107:c77-c81.
30. Naganuma T, Sugimura K, Wadw S, et al. The prognostic role of brain natriuretic peptides in hemodialysis patients. Am J Nephrol. 2002;22:437-444.
31. Cataliotti A, Malatino LS, Jougasaki M, et al. Circulating natriuretic peptide concentrations in patients with endstage renale disease: role of brain natriuretic peptide as a biomarker for ventricular remodelling. Mayo Clin Proc. 2001;76:1111-1119.